Technical Data
DARPP32, phosphorylated (Thr34) (DARPP-32, Dopamine- and cAMP-regulated Neuronal Phosphoprotein, FLJ20940, Protein Phosphatase 1 Regulatory Subunit 1B, PPP1R1B)
DARPP-32, a dopamine (DA) and cAMP-regulated ~32kD phosphoprotein that is associated with dopaminoceptive neurons bearing D-1 receptors in the basal ganglia. The protein inhibits protein phosphatase I when it is phosphorylated on Thr34. In contrast, when DARPP-32 is phosphorylated on Thr75 the protein acts as an inhibitor of PKA. Phosphorylation of DARPP-32 is thought to play a critical role in the regulation of dopaminergic neurotransmission. In addition, the activity of DARPP-32 is also thought to play important roles in the actions of alcohol, caffeine and Prozac®.

Suitable for use in Western Blot.. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Optimal dilutions to be determined by the researcher.

Positive Control:
Forskolin incubated rat caduate

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ul-20°CBlue IceHumanRabbit
Not determined
Synthetic phosphopeptide corresponding to amino acids residues surrounding the phosphorylated (Thr34) of DARPP-32.
Purified by immunoaffinity chromatography.
Supplied as a liquid in 10mM HEPES (pH 7.5), 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.
Recognizes human DARPP-32, phosphorylated at (Thr34). Species Crossreactivity: mouse and rat. Species Sequence Homology: bovine, chicken, canine and monkey.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A., O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D.C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.G., Hyman, S.E., Surmeier, D.G., Girault, J., Nestler, E.J. and Greengard, P. “DARPP-32: regulator of the efficacy of dopaminergic neurotransmission,” Science 281 (1998) 838 - 842. 2. Bibb, J.A., Snyder, G.L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A.A., Tsai, L.H., Kwon, Y.T., Girault, J.A., Czernik, A.J., Huganir, R.L., Hemmings, Jr., H.C., Nairn, A.C. and Greengard, P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signallingin neurons, Nature (London) 402 (1999) 669 - 671. 3. Maldve, R.E., Zhang, T.A., Ferrani-Kile, K., Schreiber, S.S., Lippmann, M.J., Snyder, G.L., Feinberg, A.A., Leslie, S.W., Gonzales, R.A. and Morrisett, R.A. “DARPP-32 and the regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens,” Nature Neurosci. 5 (2002) 641 - 648. 4. Lindskog, M., Svenningsson, P., Pozzi, L., Kim, Y., Fienberg, A.A., Bibb, J.A., Fredholm, B.B., Nairn, A.C., Greengard, P. and Fisone, G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine, Nature (London) 418 (2002) 774 - 778.
5. Svenningsson, P., Tzavara, E.T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D.L., Fienberg, A.A., Nomikos, G.G. and Greengard, P., “Diverse psychotomimetics act through a common signaling pathway,” Science, 302 (2003) 1412 - 1415. 6. Walaas, S.I. and Greengard, P., “DARPP-32, A dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions,” J. Neurosci. 4 (1984) 84 - 98.